NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation

Active Not RecruitingPhase 1

Sponsor: Jonsson Comprehensive Cancer Center

Conditions: Metastatic Malignant Neoplasm in the Prostate Gland, Prostate Carcinoma, Recurrent Prostate Carcinoma

Interventions: Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography

Countries: United States

This exploratory study investigates how a new imaging technique called FAPI PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with prostate cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors. The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers including prostate cancer.

Eligibility overview

Sex: MALE

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Patients who underwent a 68Ga-PSMA-11 PET/CT scan within 3 months of enrollment
* Patients who are scheduled to undergo surgical excision or biopsy of a prostate cancer primary, recurrent or metastatic lesion
* Patients can provide written informed consent
* Patients are able to remain still for duration of imaging procedure (up to one hour)

Exclusion Criteria:

* Patients with any new prostate therapy between the PSMA PET/CT and the FAP inhibitor (FAPI) PET/CT

Locations (1)

Los Angeles, California, United States